Current Perspectives in Kidney Diseases. Группа авторов
Чтение книги онлайн.
Читать онлайн книгу Current Perspectives in Kidney Diseases - Группа авторов страница 10
![Current Perspectives in Kidney Diseases - Группа авторов Current Perspectives in Kidney Diseases - Группа авторов Contributions to Nephrology](/cover_pre941610.jpg)
64 Cantaluppi V, Quercia AD, Dellepiane S, Figliolini F, Medica D, De Lena M: [New mechanisms and recent insights in the pathogenesis of acute kidney injury (AKI)]. G Ital Nefrol 2012;29:535–547.
65 Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M: Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med 2008;36:268–272.
66 Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, et al: Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open 2014;4:e003536.
67 Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, et al: Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008;19:1034–1040.
68 Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, et al: The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study. Semin Dial 2013;26:616–623.
69 Tsai AC, Ma T: Expansion of human mesenchymal stem cells in a microcarrier bioreactor. Methods Mol Biol 2016;1502:77–86.
70 González de Molina FJ, Ferrer R: Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care 2011;15:175.
71 Shaw AR, Chaijamorn W, Mueller BA: We underdose antibiotics in patients on CRRT. Semin Dial 2016;29:278–280.
Prof. Vincenzo Cantaluppi
SCDU Nefrologia e Trapianto Renale, Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale (UPO) “A. Avogadro”
Azienda Ospedaliera Universitaria “Maggiore della Carità”
Corso Mazzini 18, IT–28100 Novara (Italy)
E-Mail [email protected]
Perspectives in Acute Kidney Injury
La Manna G, Ronco C (eds): Current Perspectives in Kidney Diseases.
Contrib Nephrol. Basel, Karger, 2017, vol 190, pp 19–30 (DOI: 10.1159/000468833)
______________________
Citrate Anticoagulation during Continuous Renal Replacement Therapy
Davide Ricci · Laura Panicali · Maria Grazia Facchini · Elena Mancini
Nephrology Dialysis Hypertension Department, Teaching Hospital Policlinico S. Orsola-Malpighi, Bologna, Italy
______________________
Abstract
During extracorporeal dialysis, some anticoagulation strategy is necessary to prevent the coagulation of blood. Heparin has historically been used as an anticoagulant because of its efficacy combined with low cost. However, a variable incidence of hemorrhagic complications (5–30%) has been documented in patients undergoing continuous renal replacement therapy (CRRT) with heparin as an anticoagulant. Citrate has anticoagulation properties secondary to its ability to chelate calcium, which is necessary for the coagulation cascade. Citrate may thus be used in a regional anticoagulation (RCA), limited to the extracorporeal circuit of CRRT, to avoid systemic anticoagulation. Recent meta-analysis confirmed the advantage of RCA over heparin in terms of incidence of bleeding during CRRT. Moreover, an increase in filter lifespan is documented, with a secondary advantage in reaching the prescribed dialysis dose. In our experience, we could confirm this positive effect. In fact, with a progressive increase in the proportion of CRRT with citrate as RCA, we obtained a reduction in the number of filters used for every 72 h of treatment (from 2.4 in 2011 to 1.3 in 2015), and most importantly, a reduction in the difference between the prescribed and delivered dialysis doses (from 22 to 7%). Citrate has an intense effect on the acid-base balance as well, if fully metabolized through the Krebs cycle, due to the production of bicarbonate. Even more severely ill patients, such as those with liver dysfunction, may be treated with RCA without severe complications, because modern machines for CRRT are equipped with simple systems that are able to manage the citrate infusion and control the calcium levels, with minimal risks of metabolic derangements.
© 2017 S. Karger AG, Basel
Introduction
Continuous renal replacement therapy (CRRT) is widely used for treating acute kidney injury (AKI). Although there are several experiences on CRRT without anticoagulation [1], some anticoagulation strategy is generally thought to be required to avoid circuit blood clotting. During CRRT, blood is conducted through an extracorporeal circuit, activating coagulation by a complex interaction between patient and circuit. Critically ill patients may also develop a procoagulant state frequently due to sepsis; activation of the coagulation system is triggered by proinflammatory cytokines that enhance the expression of tissue factor on activated mononuclear and endothelial cells and simultaneously downregulate natural anticoagulants, thus initiating thrombin generation, subsequent activation of platelets, and inhibition of fibrinolysis. The beginning of clotting in the extracorporeal circuit has traditionally been attributed to contact activation of the intrinsic coagulation system. However, the bioincompatibility reaction is more complex and is incompletely understood. The activation of tissue factor, leucocytes, and platelets plays an additional role [2].
In spite of the high bleeding risk related to AKI itself [3], systemic anticoagulation with unfractioned heparin has historically been used to maintain the patency of the extracorporeal circuit for CRRT. However, a high incidence of hemorrhagic complications has been documented with wide variability (5–30%) related to differences in patient populations and anticoagulation protocols [4]. Furthermore, a kind of “inverse correlation” between the hemorrhagic risk for the patient and the coagulation risk for the circuit was established in 1996 by Wetering. The higher the attention given to avoid the risk of bleeding (by reducing heparin), the higher is the incidence of thrombotic events to the extracorporeal circuit, and vice versa [5].
To avoid this drawback, both prostaglandin E1 and prostaglandin I2 have been tested in CRRT, but their high cost and hypotension due to vasodilatation are distinct limits to their routine use [2]. Regional citrate anticoagulation (RCA) offers an attractive alternative, and the 2012 Kidney Disease Improving Global Outcomes Clinical